Pasithea Therapeutics (KTTA) Income towards Parent Company (2021 - 2026)
Pasithea Therapeutics recorded quarterly Income towards Parent Company of -$2.9 million in Q1 2026, up 71.62% quarter-over-quarter from -$10.1 million in Q4 2025, and up 19.47% year-over-year from -$2.4 million in Q1 2025.
Pasithea Therapeutics' Income towards Parent Company history runs 6 years deep, the most recent figure standing at -$2.9 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 19.47% year-over-year to -$2.9 million; the TTM figure through Mar 2026 stood at -$19.7 million (down 45.03% YoY), while the FY2025 annual figure was -$20.4 million, down 46.91% from the prior year.
- Income towards Parent Company came in at -$2.9 million for Q1 2026 at Pasithea Therapeutics, up from -$10.1 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$16895.0 in Q4 2023 to a low of -$10.1 million in Q4 2025.
- A 5-year average of -$2.5 million and a median of -$2.9 million in 2024 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company jumped 98.41% in 2023 and tumbled 18708.29% in 2024, its largest moves.
- Pasithea Therapeutics' Income towards Parent Company stood at -$1.1 million in 2022, then surged by 98.41% to -$16895.0 in 2023, then sank by 18708.29% to -$3.2 million in 2024, then sank by 218.19% to -$10.1 million in 2025, then soared by 71.62% to -$2.9 million in 2026.
- According to Business Quant data, Income towards Parent Company over the past three periods registered -$2.9 million, -$10.1 million, and -$3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Pasithea Therapeutics | 17.41 Mn | 17.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.87 Mn |
| Dec 31, 2025 | -10.11 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -3.72 Mn |
| Mar 31, 2025 | -3.56 Mn |
| Dec 31, 2024 | -3.18 Mn |
| Sep 30, 2024 | -3.00 Mn |
| Jun 30, 2024 | -3.87 Mn |
| Mar 31, 2024 | -3.86 Mn |
| Dec 31, 2023 | -16,895.00 |
| Jun 30, 2023 | -165,146.00 |
| Mar 31, 2023 | -271,869.00 |
| Dec 31, 2022 | -1.06 Mn |
| Sep 30, 2022 | -395,089.00 |
| Jun 30, 2022 | -468,535.00 |
| Mar 31, 2022 | -325,659.00 |
| Dec 31, 2021 | 630,143.00 |
| Sep 30, 2021 | -1.53 Mn |
| Jun 30, 2021 | -727,947.00 |
| Mar 31, 2021 | -549,609.00 |